Agenda

In perpetual awe of how 'simple' microbial organisms can perturb complex, multicellular eukaryotic organisms, Ami Bhatt has chosen to dedicate her research program to inspecting, characterizing and dissecting the microbe-human interface. Nowhere is the interaction between hosts and microbes more potentially impactful than in immunocompromised hosts and global settings where infectious and environmental exposures result in drastic and sometimes fatal health consequences. Ami's group identifies problems and questions that arise in the course of routine clinical care. Often in collaboration with investigators at Stanford and beyond, the group applies modern genetic, molecular and computational techniques to seek answers to these questions, better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease phenotypes.

In perpetual awe of how 'simple' microbial organisms can perturb complex, multicellular eukaryotic organisms, Ami Bhatt has chosen to dedicate her research program to inspecting, characterizing and dissecting the microbe-human interface. Nowhere is the interaction between hosts and microbes more potentially impactful than in immunocompromised hosts and global settings where infectious and environmental exposures result in drastic and sometimes fatal health consequences. Ami's group identifies problems and questions that arise in the course of routine clinical care. Often in collaboration with investigators at Stanford and beyond, the group applies modern genetic, molecular and computational techniques to seek answers to these questions, better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease phenotypes.

Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 330 research articles and is the holder of 50 US patents, and has been honored as one of the top 25 inventors at Stanford University. Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for “Bio-agent protection” grant, $3million, from the FDA for a “Cross-Species Immune System Reference”, and received the award for “Outstanding Research Achievement in 2011” from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA) and another grant to study the effects of Zika and Ebola viruses on humans (also from the FDA). Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve the public welfare. Dr. Nolan was the founder of Rigel Inc. (NASDAQ: RIGL), and Nodality, Inc. (a diagnostics development company), BINA (a genomics computational infrastructure company sold to Roche Diagnostics), Founder of Apprise (sold to Roche Sequencing Solutions), co-Founder of Ionpath, co-Founder of Akoya, and serves on the Boards of Directors of several companies as well as consults for other biotechnology companies. DVS Sciences, on which he was Chair of the Scientific Advisory Board, recently sold to Fluidigm for $207 million dollars (2014) on an investment of $14 million. Dr. Nolan is a member of the Parker Institute for Cancer Immunotherapy at Stanford. His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call “CyTOF” and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches use an advanced ion plasma source to determine the levels of tagged reagents bound to cells—enabling a vast increase in the number of parameters that can be measured per cell—either as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts with another imaging platform termed CODEX (Akoya, Inc.) that inexpensively converts fluorescence scopes to high dimensional imaging platforms. Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers and their interactions with the immune system—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.

Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 330 research articles and is the holder of 50 US patents, and has been honored as one of the top 25 inventors at Stanford University. Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for “Bio-agent protection” grant, $3million, from the FDA for a “Cross-Species Immune System Reference”, and received the award for “Outstanding Research Achievement in 2011” from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA) and another grant to study the effects of Zika and Ebola viruses on humans (also from the FDA). Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve the public welfare. Dr. Nolan was the founder of Rigel Inc. (NASDAQ: RIGL), and Nodality, Inc. (a diagnostics development company), BINA (a genomics computational infrastructure company sold to Roche Diagnostics), Founder of Apprise (sold to Roche Sequencing Solutions), co-Founder of Ionpath, co-Founder of Akoya, and serves on the Boards of Directors of several companies as well as consults for other biotechnology companies. DVS Sciences, on which he was Chair of the Scientific Advisory Board, recently sold to Fluidigm for $207 million dollars (2014) on an investment of $14 million. Dr. Nolan is a member of the Parker Institute for Cancer Immunotherapy at Stanford. His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call “CyTOF” and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches use an advanced ion plasma source to determine the levels of tagged reagents bound to cells—enabling a vast increase in the number of parameters that can be measured per cell—either as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts with another imaging platform termed CODEX (Akoya, Inc.) that inexpensively converts fluorescence scopes to high dimensional imaging platforms. Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers and their interactions with the immune system—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.

Dr. Menon is the Rachel L. and Walter F. Nichols, MD, Professor of Psychiatry & Behavioral Sciences and, Professor, by courtesy, of Neurology & Neurological Sciences and Education at Stanford University. Dr. Menon is director of the Stanford Cognitive and Systems Neuroscience Laboratory, which seeks to advance fundamental knowledge of human brain function and dysfunction, and to use this knowledge to help children and adults with psychiatric and neurological disorders. Research in Dr. Menon's lab emphasizes a tight integration of cognitive, behavioral, neuroscience and computational methodologies. Students and researchers in his lab come from a wide range of disciplines, including psychiatry, neurology, psychology, neuroscience, electrical and biomedical engineering, and computer science, to conduct research in a highly interdisciplinary setting. Dr. Menon received his BSc (Honors) in physics from the Indian Institute of Technology and his PhD in computer science from the University of Texas at Austin. He did a postdoctoral fellowship in neurophysiology at the University of California, Berkeley under the direction of Prof. Walter J. Freeman, III. He came to Stanford University as a Sinclair Foundation Research Fellow and joined the faculty in 2000. Over the past two decades, Dr. Menon’s research has led to major breakthroughs in our understanding of the architecture, function, and development of these large-scale distributed human brain networks. Dr. Menon and his team were among the first to discover that the human brain is organized into specialized and interacting networks of brain regions, which has resulted in a paradigm shift in how we investigate human brain function and cognition. Virtually every psychiatric and neurological disorder has been probed with the scientific framework Dr. Menon and his team first developed. This includes discovery of the default mode, frontoparietal, and salience networks, and their functions, which have led to elucidation of how deficits in access, engagement and disengagement of large-scale brain networks play a prominent role in psychopathology, providing novel insights into brain mechanisms underlying cognitive, affective, and social function and dysfunction that cut across multiple neurological and psychiatric disorders. Dr. Menon’s research has been cited over 90,000 times, with an h-index of 125 (Google Scholar). Dr. Menon is a ISI Highly Cited Researcher in Neuroscience (2013, 2014, 2015, 2016, 2017, 2018; ISI, Thompson Reuters), and in 2019 and 2020 he was named an ISI Highly Cited Researcher with Cross-Field impact.

Dr. Menon is the Rachel L. and Walter F. Nichols, MD, Professor of Psychiatry & Behavioral Sciences and, Professor, by courtesy, of Neurology & Neurological Sciences and Education at Stanford University. Dr. Menon is director of the Stanford Cognitive and Systems Neuroscience Laboratory, which seeks to advance fundamental knowledge of human brain function and dysfunction, and to use this knowledge to help children and adults with psychiatric and neurological disorders. Research in Dr. Menon's lab emphasizes a tight integration of cognitive, behavioral, neuroscience and computational methodologies. Students and researchers in his lab come from a wide range of disciplines, including psychiatry, neurology, psychology, neuroscience, electrical and biomedical engineering, and computer science, to conduct research in a highly interdisciplinary setting. Dr. Menon received his BSc (Honors) in physics from the Indian Institute of Technology and his PhD in computer science from the University of Texas at Austin. He did a postdoctoral fellowship in neurophysiology at the University of California, Berkeley under the direction of Prof. Walter J. Freeman, III. He came to Stanford University as a Sinclair Foundation Research Fellow and joined the faculty in 2000. Over the past two decades, Dr. Menon’s research has led to major breakthroughs in our understanding of the architecture, function, and development of these large-scale distributed human brain networks. Dr. Menon and his team were among the first to discover that the human brain is organized into specialized and interacting networks of brain regions, which has resulted in a paradigm shift in how we investigate human brain function and cognition. Virtually every psychiatric and neurological disorder has been probed with the scientific framework Dr. Menon and his team first developed. This includes discovery of the default mode, frontoparietal, and salience networks, and their functions, which have led to elucidation of how deficits in access, engagement and disengagement of large-scale brain networks play a prominent role in psychopathology, providing novel insights into brain mechanisms underlying cognitive, affective, and social function and dysfunction that cut across multiple neurological and psychiatric disorders. Dr. Menon’s research has been cited over 90,000 times, with an h-index of 125 (Google Scholar). Dr. Menon is a ISI Highly Cited Researcher in Neuroscience (2013, 2014, 2015, 2016, 2017, 2018; ISI, Thompson Reuters), and in 2019 and 2020 he was named an ISI Highly Cited Researcher with Cross-Field impact.

Dr. May Chen specializes in medical oncology with expertise in treating gastrointestinal and women’s cancers. Her interests include cancer genetics and genomics, using the latest advances to treat complicated diseases. Dr. Chen is skilled in caring for advanced cancer patients, including managing complications from advanced disease, side effects, and using integrative modalities to enhance the cancer patient experience.

My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984) at Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). Vice President (2022-3), President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI, many others) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Aristotle U Thessaloniki (2023). Multiple honorary lectureships/visiting professorships (Caltech, Oxford, LSHTM, Yale, U Utah, U Conn, UC Davis, U Penn, Wash U St. Louis, NIH among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 9 literary books, three of them shortlisted for best book of the year Anagnostis awards in Greece. Latest book (in English, published in 2022) is 2 books hyperlinked to each other. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=255 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make a lot of errors, I need to revisit my writings multiple times before publishing, and I see no reason to make a fool of myself more frequently than it is sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.

My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984) at Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). Vice President (2022-3), President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI, many others) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Aristotle U Thessaloniki (2023). Multiple honorary lectureships/visiting professorships (Caltech, Oxford, LSHTM, Yale, U Utah, U Conn, UC Davis, U Penn, Wash U St. Louis, NIH among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 9 literary books, three of them shortlisted for best book of the year Anagnostis awards in Greece. Latest book (in English, published in 2022) is 2 books hyperlinked to each other. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=255 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make a lot of errors, I need to revisit my writings multiple times before publishing, and I see no reason to make a fool of myself more frequently than it is sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.

My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984) at Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). Vice President (2022-3), President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI, many others) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Aristotle U Thessaloniki (2023). Multiple honorary lectureships/visiting professorships (Caltech, Oxford, LSHTM, Yale, U Utah, U Conn, UC Davis, U Penn, Wash U St. Louis, NIH among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 9 literary books, three of them shortlisted for best book of the year Anagnostis awards in Greece. Latest book (in English, published in 2022) is 2 books hyperlinked to each other. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=255 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make a lot of errors, I need to revisit my writings multiple times before publishing, and I see no reason to make a fool of myself more frequently than it is sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.

Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation. Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”

Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation. Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”